The estimated Net Worth of Stephen B. Shohet is at least 4.02 百万$ dollars as of 10 December 2018. Stephen Shohet owns over 58,557 units of Amphastar Pharmaceuticals Inc stock worth over 4,023,083$ and over the last 10 years Stephen sold AMPH stock worth over 0$.
Stephen has made over 15 trades of the Amphastar Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Stephen exercised 58,557 units of AMPH stock worth 858,446$ on 10 December 2018.
The largest trade Stephen's ever made was exercising 58,557 units of Amphastar Pharmaceuticals Inc stock on 10 December 2018 worth over 858,446$. On average, Stephen trades about 11,376 units every 79 days since 2014. As of 10 December 2018 Stephen still owns at least 89,263 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Stephen Shohet stock trades at the bottom of the page.
Stephen's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over 72,457,295$ worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth 921,987$ . The most active insiders traders include Jack Y.Luo Mary Z. Zhang、Richard K Prins、William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,459,051$. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth 139,410$.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: